Wolfe Research Downgrades Alpine Immune Sciences to Peer Perform
Portfolio Pulse from Benzinga Newsdesk
Wolfe Research analyst Andy Chen downgraded Alpine Immune Sciences (NASDAQ:ALPN) from Outperform to Peer Perform, indicating a change in the firm's outlook on the stock.
April 11, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Alpine Immune Sciences was downgraded by Wolfe Research from Outperform to Peer Perform, reflecting a more cautious view on the company's stock.
Analyst downgrades typically lead to a negative short-term reaction in the stock market as they suggest a less optimistic view on the company's future performance. Given that this downgrade comes from a reputable firm, it's likely to influence investors' perceptions and could lead to a decrease in stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100